Not finding it? Sign in to also search OpenAlex live.
-
Corrigendum to “De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR− phase II trial: efficacy, safety, and predictive markers for 12weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel”
Ulrike Anneliese Nitz, Oleg Gluz, Mathias Christgen, E.‐M. Grischke, Doris Augustin, Sherko Küemmel, +14 more
1citations -
Corrigendum to ‘Final Analysis Results and Patient-Reported Outcomes From DESTINY-Lung02—A Dose-Blinded, Randomized, Phase 2 Study of Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic NSCLC’ [Journal of Thoracic Oncology Volume 20 Issue 12 (2025) 1814-1828]
Pasi Antero Janne, Yasushi Goto, Toshio Kubo, Kiichiro Ninomiya, Sang-We Kim, David Planchard, +15 more
0citations
3 results